Strong Dupixent + Vaccines powers upward revision to outlook
30/07/21 -"Sanofi witnessed remarkable growth in Q2, with strong growth in the high-margin Dupixent and Vaccines business being complemented by the recovery in the consumer business. Moreover, the improving ..."
Pages
64
Language
English
Published on
30/07/21
You may also be interested by these reports :
12/02/26
Ipsen concluded 2025 with sales and profitability exceeding expectations, driven by growth across all therapeutic areas. The 2026 guidance surpassed ...
12/02/26
Since the beginning of 2025, and even after the new CEO (Maziar Mike Doustdar) was appointed in August 2025, Novo has downgraded growth expectations ...
10/02/26
Even though Q4 25 operating profitability missed the street’s expectations, Astra met its full-year CER guidance. The Q4 performance was largely ...
06/02/26
Q4 ‘25 results exceeded consensus, as Lundbeck met its 2025 guidance. Strong growth for depression treatment Rexulti and migraine medicine Vyepti ...